Best Fit Profiles
- biologically-focused longevity protocols and epigenetic age tracking
Epigenetic aging and metabolic support
Alpha-Ketoglutarate
AKG is a key TCA cycle intermediate with preliminary human data suggesting reduction in biological age markers. Calcium AKG showed promise in one RCT but larger trials are needed.
Evidence Level B
Evidence and Risk Labels
Evidence A/B/C reflects research maturity, and risk levels reflect monitoring needs. These labels support comparison, not diagnosis or treatment decisions.
See full scoring guideClinical Snapshot
- Effect Size
- Modest reduction in epigenetic age markers in early human trials; metabolic effects well established in cell models
- Safety
- Low Risk
Limited long-term human safety data; avoid in active cancer contexts without medical supervision.
Research Dosing
This reflects common ranges and protocols used in published studies, not personal medical advice.
- Typical Daily Dose
- 1000-3000 mg
- Timing
- With meals
- Protocol Duration in Studies
- Ongoing; 6-month trial minimum for epigenetic readout
Calcium salt form used in the primary aging RCT; pure AKG has different absorption kinetics.